AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get moving
Target
Upside 114%
Price (€) 4.53
Market Cap (€M) 164
Perf. 1W: 3.08%
Perf. 1M: 30.4%
Perf. 3M: 16.0%
Perf Ytd: 37.3%
10 day relative perf. to stoxx600: 7.09%
20 day relative perf. to stoxx600: 18.6%
EPS change31/08/2021

Change in EPS2021 : € -0.28 vs 0.18ns
2022 : € 0.63 vs 0.91-30.7%

We have fine-tuned our numbers on the back of the FY20 detailed accounts. Forecasts were also partly amended but net results remain low in the next few years which explains why a small change in the estimates translates into a more significant one in percentage terms at the EPS level.



Updates
.